Bryant Harbourne

Bryant Harbourne

Auto-generated profile, based on publicly available information

Bryant Harbourne

Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2018 in eLife
Verified
Journal Article
Open access
AUArun Unni
Arun Unni
BHBryant Harbourne
Bryant Harbourne
MOMin Hee Oh
Min Hee Oh
SWSophia Wild
Sophia Wild
JFJohn R Ferrarone
John R Ferrarone
HVHarold Varmus
Harold Varmus
Synthetic lethality results when mutant KRAS and EGFR proteins are co-expressed in human lung adenocarcinoma (LUAD) cells, revealing the biological basis for mutual exclusivity of KRAS and EGFR mutations. We have now defined the biochemical events responsible for the toxic effects by combining pharmacological and genetic approaches and to show that signaling through extracellular signal-regulated kinases (ERK1/2) mediates the toxicity. These findings imply that tumors with mutant oncogenes in the RAS pathway must restrain the activity of ERK1/2 to avoid toxicities and enable tumor growth. A dual specificity phosphatase, DUSP6, that negatively regulates phosphorylation of (P)-ERK is up-regulated in EGFR- or KRAS-mutant LUAD, potentially protecting cells with mutations in the RAS signaling pathway, a proposal supported by experiments with DUSP6-specific siRNA and an inhibitory drug. Targeting DUSP6 or other negative regulators might offer a treatment strategy for certain cancers by inducing the toxic effects of RAS-mediated signaling.

16 October 2018 in OncoImmunology
Verified
Journal Article
Closed access
EHE.C. Halvorsen
E.C. Halvorsen
SFS.E. Franks
S.E. Franks
BWBrennan Wadsworth
Brennan Wadsworth
BHB.T. Harbourne
B.T. Harbourne
RCR.A. Cederberg
R.A. Cederberg
KBKevin L Bennewith
Kevin L Bennewith
Regulatory T cells (Tregs) facilitate primary and metastatic tumour growth through the suppression of anti-tumour immunity. Emerging evidence suggests a distinct role for Tregs in mediating tissue repair and barrier integrity in the lungs by IL-33 mediated production of the growth factor amphiregulin (AREG). Dependent on the type of cancer and local microenvironment, AREG may induce tumour cell proliferation, invasion, migration or resistance to apoptosis by signaling through the epidermal growth factor receptor (EGFR). We have found that IL-33 is dramatically increased in and around metastatic tumour foci in the lungs of mice bearing orthotopic murine mammary tumours. We observed that Tregs express significantly more of the IL-33 receptor, ST2, relative to conventional T cells, that ST2+ Tregs accumulate in the lungs of metastatic tumour-bearing mice, and that ST2+ Tregs produce significantly more AREG than ST2− Tregs. The intranasal administration of recombinant IL-33 increased the proportion of AREG producing ST2+ Tregs and enhanced the level of phosphorylated EGFR in the metastatic lungs. While recombinant AREG did not impact mammary tumour cell proliferation in vitro despite inducing a dose-dependent increase in phosphorylated EGFR, intranasal administration of AREG resulted in a ten-fold increase in pulmonary metastatic tumour burden in vivo. Further, the intranasal administration of recombinant IL-33 significantly increased metastatic tumour burden in the lungs in an amphiregulin-dependent manner. These data identify ST2+ Tregs as a microenvironmental source of AREG in the lungs of mice with orthotopic metastatic mammary tumours and highlight an important role for AREG in promoting metastatic tumour growth in the lungs.

1 April 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
HOHannah O’fArrell
Hannah O’fArrell
BHBryant Harbourne
Bryant Harbourne
ZKZimple Kurlawala
Zimple Kurlawala
YIYusuke Inoue
Yusuke Inoue
ANAmy L. Nagelberg
Amy L. Nagelberg
WLWilliam Lockwood
William Lockwood